Haemonetics Corporation (HAE) Stock Forecasts

Haemonetics (HAE) and Twist Bioscience (TWST) shares reached over 5-year highs. HAE rose 2% due to a renewed deal with CSL Plasma, with Citi upgrading it to 'Buy' and raising its target to $123. TWST surged 11% following its AI drug discovery partnership with Eli Lilly's TuneLab, with Leerink raising its target to $160.

Haemonetics (HAE) announced a new deal with CSL Plasma to supply its NexSys PCS platforms and apheresis kits for U.S. plasma collection centers. The contract, following FDA approval, does not have minimum purchase requirements. HAE shares rose 15% in after-hours trading, reaching $107. Analysts estimate potential revenue of $183M-$223M annually if CSL fully switches back, with a 6%-8% growth rate and 10%-20% pricing premium.

Haemonetics Corp (HAE) hit a 52-week high of $106.64, up 92.73% over a year. The medical tech firm's stock has surged 72.49% in six months and 14.57% in the past week. Q1 earnings beat estimates, with revenue at $339M. BTIG raised its price target to $96. HAE signed a supply deal with CSL Plasma.

Haemonetics Corporation (NYSE:HAE) rose 15.9% after announcing a supply agreement with CSL Plasma, adding to its 91.88% surge since being identified by InvestingPro's AI models. The company reported Q1 2027 revenue of $339.4M and adjusted EPS of $1.14, raising its full-year revenue growth outlook to 5-8%. InvestingPro's AI-powered stock picker has identified multiple stocks with significant gains, including Haemonetics, which was highlighted for its valuation, profitability, and growth potential

Haemonetics (NYSE:HAE) shares rose 16.3% after it announced a non-exclusive U.S. supply agreement with CSL Plasma. Signed Aug. 14, 2026, it allows CSL to use Haemonetics NexSys PCS devices with Persona PLUS and buy related disposables, with no minimum purchase commitments. Haemonetics did not revise fiscal 2027 guidance and plans an update at its Q2 earnings call in Nov. 2026.

Haemonetics (HAE) shares rose about 6.6% in pre-open after the company filed an 8-K for a non-exclusive supply agreement with CSL Plasma. The deal lets CSL deploy Haemonetics NexSys PCS devices with Persona PLUS and buy related disposables at U.S. centers. Investors also cited Haemonetics’ Aug. 6 Q1 FY2027 results: $339.4M revenue, $1.14 adjusted EPS, and raised FY2027 growth guidance to 5%–8%, plus analyst target increases.